Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers

News
Video

In a recent interview, Jean Seely, M.D., discussed a new study showing significantly higher rates of mastectomy, chemotherapy use and breast cancer-specific death in women with symptom-detected cancer in comparison to those with screen-detected breast cancer.

New research reveals that symptom-detected breast cancer is far more common among age groups that have less mammography screening (women in their 40s and those 75 years of age or older) in comparison to age groups that have more routine screening (women between the ages of 50-74).

For the retrospective study, recently published in Radiology: Imaging Cancer, researchers reviewed data for 821 women with breast cancer (mean age of 62.5). The study authors found that 72.9 percent of women in their 40s and 70.4 percent of women > 75 years of age and older had symptom-detected breast cancer in comparison to 49.5 percent of women in their 50s and 33.3 percent of women 60 to 74 years of age.

The researchers also noted that symptom-detected breast cancer was associated with significantly higher rates of mastectomy, chemotherapy treatment and advanced presentations, noted lead study author Jean Seely, M.D., FRCPC, in a recent interview.

“The women that were symptom detected had a 6.6 times higher rate of (having) advanced cancer … We found (they were) twice as likely to be needing chemotherapy and also almost twice as likely to need a mastectomy. It just meant that they were much more advanced at diagnosis when they were symptom detected as compared to many fewer who were screen detected (having) advanced (cancer presentation) at diagnosis,” noted Dr. Seely, a professor in the Department of Radiology at Ottawa University.

Dr. Seely also pointed out that 21.7 percent of women with symptom-detected cancer died within the 6.7-year follow-up period in comparison to 14.5 percent of women with screen-detected cancers. The mortality rate was 63 percent higher for women with symptom-detected cancers, according to Dr. Seely.

“I think that really drilled home the need to really encourage early detection of breast cancer with screening and to show that the way that we detect a breast cancer has such an impact on predicting their outcome,” emphasized Dr. Seely, the head of the Breast Imaging Section in the Department of Medical Imaging at Ottawa Hospital. “We as radiologists should be tracking this. We should be reporting this, and I think it will help our referring providers understand the impact of early detection and screening.”

(Editor’s note: For related content, see “Mammography Study Shows Key Findings with Ai in DBT Screening,” “Recent Mammography Screening in Seniors Associated with 54 Percent Lower Risk of Later-Stage Diagnosis” and “Mammography Study Reveals Mixed Results with Standalone AI Assessment for Post-Mastectomy Surveillance.”)

For more insights from Dr. Seely, watch the video below.

Recent Videos
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.